Neurala Biosciences

Actual: Jun 1, 2024

Phase 1 PoC completed: 9 healthy volunteers, 17 dosing sessions at St Vincent's Hospital Melbourne. Botanically derived purified DMT + 3 harmala alkaloids. MEQ-30 scores ~76, 5D-ASC ~56 — exceeding published psilocybin and LSD benchmarks. Well tolerated, no serious adverse events.

Why it matters: First controlled clinical data for a pharmaceutical-grade oral DMT-harmala (pharmahuasca) formulation. The 3-5 hour duration aligns with standard therapy sessions, unlike IV DMT (15 min) or psilocybin (6-8 hrs). Intensity metrics exceeding psilocybin/LSD benchmarks suggest potent therapeutic potential.

Actual: Feb 1, 2025

Phase 1 results published in Scientific Reports. Acute experience intensity correlated with persisting psychological benefits.

Why it matters: Peer-reviewed publication in a high-impact Nature journal builds scientific credibility and supports regulatory submissions for the second-generation NBX-100 formulation.

Actual: Jan 15, 2026

GMP drug product for NBX-100 (2nd gen) completed final release testing. Second-generation formulation incorporates proprietary structural refinements to harmala alkaloids.

Why it matters: GMP manufacturing completion is the last prerequisite before Phase 1 dosing can begin. The proprietary harmala modifications differentiate NBX-100 from generic pharmahuasca formulations and strengthen the IP position.

Actual: Feb 1, 2026

HREC (Human Research Ethics Committee) and TGA regulatory approvals granted for Phase 1 PK/PD study at CMAX Clinical Research, Adelaide.

Why it matters: Dual approval (ethics + regulatory) clears NBX-100 for first-in-human dosing of the second-generation formulation. Australian CTN scheme allows faster trial initiation than FDA IND process.

Actual: Feb 24, 2026

Spyros Papapetropoulos, MD, PhD appointed Board Chair. Former President & CEO of Neuphoria Therapeutics (Nasdaq: NEUP); 20+ years CNS drug development experience; 170+ publications.

Why it matters: Appointment of a seasoned CNS drug development executive with Nasdaq CEO experience signals preparation for later-stage clinical development and potential US expansion. Papapetropoulos' IND/NDA submission experience is critical for future FDA interactions.

Actual: Feb 16, 2026

Ab Initio Pharma (Sydney) engaged to support GMP manufacturing and development of NBX-200, funded by Australian government grant. Formulation development aligned with regulatory requirements for future clinical studies.

Why it matters: Dedicated GMP manufacturing partner and government co-funding de-risks NBX-200 development. Intranasal DMT-harmala (30-50 min) would offer the shortest controlled psychedelic experience in clinical development — ideal for clinic-based dosing without full-day sessions.